Results 41 to 50 of about 5,515 (141)

Ivabradine

Reactions Weekly, 2012
Scheinman, Melvin M., Vedantham, Vasanth
  +6 more sources

Management of Stable Angina with Ivabradine as Safe Alternative to Patients with Myasthenia Gravis

Case Reports in Neurological Medicine, 2016
Management of cardiac symptoms in myasthenia gravis (MG) patients can be challenging. The aim of this report is to describe the safe use of ivabradine for stable angina in MG patients. A 48 y.o.
Giuliano Ohde Dalledone, Gustavo Lenci Marques, Renata Dal-Prá Ducci, Arnaldo Laffitte Stier Junior, Cláudia Suemi Kamoi Kay, Lineu Cesar Werneck, Paulo José Lorenzoni, Rosana Herminia Scola   +7 more
doaj   +1 more source

Ivabradine Prevents Heart Rate Acceleration in Patients with Chronic Obstructive Pulmonary Disease and Coronary Heart Disease after Salbutamol Inhalation

Pharmaceuticals, 2012
Accelerated sinus rhythm is an important side effect of inhaled salbutamol which is especially harmful in patients with chronic obstructive pulmonary disease (COPD) and coronary heart disease (CHD). Cross-over, randomized, open label study design.
Uta C. Hoppe, Shamil Zagidullin, Guzel Abdrahmanova, Naufal Zagidullin, Rustem Zulkarneev   +4 more
doaj   +1 more source

Energetic microdomains and the vascular control of neuronal and muscle excitability: Toward a unified model

The Journal of Physiology, EarlyView.
Abstract figure legend The capillary–mitochondria–ion channel (CMIC) axis scales structural resources to match functional workload. (Left) In settings of restricted energetic capacity (e.g. cortical neurons), sparse capillary networks and modest mitochondrial pools set a lower energetic ceiling, sufficient to support phasic, low‐workload excitability. (
L. Fernando Santana, Scott Earley
wiley   +1 more source

A possibility to interchange heart rate-slowing therapy with ivabradine and atenolol in patients with stable angina pectoris

Терапевтический архив, 2013
AIM: To evaluate the efficiency and safety of an interchange of atenolol and ivabradine in patients who had stable angina pectoris without myocardial infarction in the history and left ventricular (LV) systolic dysfunction/MATERIAL AND METHODS: The trial
A A Shavarov, G K Kiiakbaev, Zh D Kobalava   +2 more
doaj  

Cost‐Effectiveness of Ivabradine for Heart Failure in the United States

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundIvabradine is a heart rate–lowering agent approved to reduce the risk of hospitalization for worsening heart failure. This study assessed the cost‐effectiveness of adding ivabradine to background therapy in the United States from the ...
Anuraag R. Kansal, Martin R. Cowie, Adrian Kielhorn, Stanimira Krotneva, Ali Tafazzoli, Ying Zheng, Nicole Yurgin   +6 more
doaj   +1 more source

Postural Orthostatic Tachycardia Syndrome Presenting With Recurrent Syncope After Cervical Spinal Cord Injury

Clinical Case Reports, Volume 14, Issue 3, March 2026.
ABSTRACT Syncope is a manifestation of autonomic dysfunction after high spinal cord injury. However, it is rarely reported as a feature of postural orthostatic tachycardia syndrome (POTS) after spinal cord injury. This case report describes a male in his 50s suffering from C2 spinal cord injury who developed recurrent postural syncope post‐injury ...
Yonghong Liu, Boyan Fang, Qiaoxia Zhen
wiley   +1 more source

Phenotypes and Clinical Outcome of Heart Failure With Preserved Ejection Fraction Patients in China: Findings From the Chinese Cardiovascular Association Database‐Heart Failure Center Registry

MedComm, Volume 7, Issue 3, March 2026.
Structured graphical abstract‐text element Key Question It remains unclear whether patients with heart failure with preserved ejection fraction (HFpEF) in different phenotypes also have various clinical outcomes. Key Finding Significant differences existed in baseline characteristics and outcomes among different phenotypes; patients with HFpEF‐3 (right
Shuai Yuan, Zhonglei Xie, Xiaotong Cui, Shun Yao, Yamei Xu, Yanyan Wang, Yu Song, Kai Hu, Yugang Dong, Yuhua Liao, Weimin Li, Xinli Li, Jiefu Yang, Jingmin Zhou, Junbo Ge   +14 more
wiley   +1 more source

Ivabradine could not decrease mitral regurgitation triggered atrial fibrosis and fibrillation compared with carvedilol

ESC Heart Failure
Background Ivabradine, a medical treatment for heart failure (HF), reduces heart rate (HR) and prolongs diastolic perfusion time. It is frequently prescribed to patients with HF who have a suboptimal response or intolerance to beta‐blockers. Degenerative
Wei‐Chieh Lee, Yu‐Wen Lin, Jhih‐Yuan Shih, Zhih‐Cherng Chen, Nan‐Chun Wu, Wei‐Ting Chang   +5 more
doaj   +1 more source

Heart rate manipulation in dilated cardiomyopathy: Assessing the role of Ivabradine

Indian Heart Journal, 2018
Background: Heart rate (HR) reduction is of benefit in chronic heart failure (HF). The effect of heart rate reduction using Ivabradine on various echocardiographic parameters in dilated cardiomyopathy has been less investigated.
Deep Chandh Raja, Aditya Kapoor, Archana Sinha, Shiridhar Kashyap, Roopali Khanna, Sudeep Kumar, Naveen Garg, Satyendra Tewari, Pravin Goel   +8 more
doaj   +1 more source